Revenue growth accelerated to 25% YoY with strong U.S. (41%) and APAC (33%) performance, and the company reiterated its path to positive adjusted EBITDA in H2 2027. Monitor Q4 revenue for FX headwind impact and the ramp of new BioPharma partnerships.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $6.91entry
- T+1 · 13d ago +0.87%α −0.78% · $6.97
- T+5 · 7d ago +13.75%α +14.34% · $7.86
- T+10 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sophia Genetics reported Q3 2026 revenue of $24.3M, up 25% YoY, beating the $24.0M consensus. GAAP EPS was -$0.24, below the consensus estimate of -$0.20, resulting in an EPS miss. The company guided full-year 2026 revenue to the upper end of its $94M-$96M range and narrowed adjusted EBITDA loss guidance to $29M-$32M, improving from $41.5M in FY 2025.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $24.3M, up 25% YoY, above $24.0M consensus
- GAAP EPS -$0.24 vs consensus -$0.20 (miss)
- Adjusted EBITDA loss improved 31% YoY to $6.1M
- Full-year 2026 revenue guided to upper end of $94M-$96M range
- Adjusted EBITDA loss guidance $29M-$32M, improved from $41.5M in FY 2025
- Record 118,000 analyses on SOPHiA DDM, 19% YoY volume growth
- Net Dollar Retention increased to 118% from 108% a year ago
- Signed 30 new core genomics customers in Q3
- Closed three material BioPharma deals including two CDx programs and a multimodal AI project
Financial Impact
Revenue beat consensus by $0.3M (1.3%); EPS missed by $0.04 (20%); adjusted EBITDA loss improved $2.8M YoY
Risk Factors
- Foreign exchange headwinds may pressure Q4 2026 revenue
- GAAP net loss increased 1% YoY to $20.3M
- EPS missed consensus by 20%
- Litigation expenses from Guardant Health lawsuits continue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302927003 |
Track record
47 reports on SOPH
5 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +64.11% at T+60 after the Jun 4, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 17, 2026today Insider Cluster Neutral 3/10 Entry $7.45 Now $7.45 −0.00% settles Nov 25
- Nov 16, 2026today 144 Neutral 2/10 Entry $7.44 Now $7.45 +0.13% settles Nov 24
- Nov 12, 20265d ago Insider Cluster Mixed 4/10 Entry $8.21 Now $7.45 −9.26% settles Nov 20
- Nov 12, 20265d ago SC 13D/A Neutral 3/10 Entry $7.86 Now $7.45 −5.22% settles Nov 19
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $7.86 Now $7.45 −5.22% due Nov 17
- Nov 9, 20268d ago Insider Cluster Bullish 4/10 Entry $7.86 Now $7.45 −5.22% due Nov 17
- Nov 3, 202614d ago 6-K Neutral 5/10 No price data
- Nov 3, 202614d ago Press Release Neutral 5/10 Viewing Entry $6.91 to $7.86 Now $7.45 +7.81% ▲ +13.75% +14.34% vs SPY
- Oct 14, 20264w ago Insider Cluster Neutral 2/10 Entry $7.29 to $7.05 Now $7.45 +2.19% ▼ −3.29% −2.28% vs SPY
- Oct 5, 20266w ago 144 Neutral 2/10 Entry $7.38 to $7.09 Now $7.45 +0.95% ▼ −3.93% −3.79% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers